See more : Nick Scali Limited (NCK.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zhejiang Ausun Pharmaceutical Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Cresco Labs Inc. (CL.CN) Income Statement Analysis – Financial Results
- MedFirst Healthcare Services, Inc. (4175.TWO) Income Statement Analysis – Financial Results
- B2Holding ASA (B2H.OL) Income Statement Analysis – Financial Results
- Sensus Healthcare, Inc. (SRTS) Income Statement Analysis – Financial Results
- FISHGUARD & ROSSLARE RAILWAYS & (72GU.L) Income Statement Analysis – Financial Results
Zhejiang Ausun Pharmaceutical Co., Ltd. (603229.SS)
About Zhejiang Ausun Pharmaceutical Co., Ltd.
Zhejiang Ausun Pharmaceutical Co., Ltd. develops, produces, and sells specialty drug substances and pharmaceutical intermediates. It offers fluorine products, prostaglandins, antimicrobials, and oncology products. The company also provides products for liver disease, respiratory system, and cardiac and cerebral vessels, as well as CNS indications. In addition, it is involved in the processing, and research and development business. The company was founded in 2010 is based in Linhai, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 816.77M | 764.55M | 569.70M | 409.25M | 307.91M | 243.89M | 240.19M | 198.84M | 262.67M | 201.42M | 120.95M | 58.93M |
| Cost of Revenue | 367.15M | 370.79M | 257.58M | 178.30M | 148.47M | 134.98M | 95.11M | 88.76M | 127.09M | 92.70M | 64.78M | 43.34M |
| Gross Profit | 449.61M | 393.75M | 312.12M | 230.95M | 159.44M | 108.90M | 145.08M | 110.08M | 135.57M | 108.72M | 56.17M | 15.59M |
| Gross Profit Ratio | 55.05% | 51.50% | 54.79% | 56.43% | 51.78% | 44.65% | 60.40% | 55.36% | 51.61% | 53.98% | 46.44% | 26.46% |
| Research & Development | 78.06M | 67.07M | 68.82M | 50.77M | 47.75M | 34.37M | 29.84M | 23.48M | 31.46M | 26.92M | 13.95M | 4.11M |
| General & Administrative | 52.10M | 39.77M | 33.76M | 27.16M | 24.26M | 17.20M | 16.08M | 9.00M | 11.24M | 31.27M | 29.04M | 8.58M |
| Selling & Marketing | 18.14M | 20.76M | 7.15M | 6.78M | 8.99M | 6.37M | 5.35M | 4.41M | 4.70M | 3.25M | 2.43M | 868.92K |
| SG&A | 70.24M | 60.53M | 40.92M | 33.94M | 33.25M | 23.57M | 21.42M | 13.41M | 15.93M | 34.52M | 31.47M | 9.45M |
| Other Expenses | 10.49M | 52.06M | 42.89M | 25.61M | 18.76M | 1.59M | -1.66M | 2.64M | 4.97M | 747.52K | -277.71K | -53.80K |
| Operating Expenses | 158.79M | 179.66M | 152.63M | 110.32M | 99.75M | 78.39M | 67.23M | 52.96M | 62.63M | 73.41M | 31.64M | 9.46M |
| Cost & Expenses | 525.94M | 550.46M | 410.20M | 288.62M | 248.22M | 213.37M | 162.34M | 141.72M | 189.72M | 166.10M | 96.42M | 52.80M |
| Interest Income | 30.56M | 8.22M | 5.78M | 7.65M | 5.43M | 2.52M | 2.71M | 358.73K | 283.74K | 125.21K | 4.23M | 2.26M |
| Interest Expense | 8.27M | 6.11M | 1.47M | 1.38M | 2.52M | 3.07M | 2.53M | 3.00M | 4.19M | 5.07M | 0.00 | 0.00 |
| Depreciation & Amortization | 40.59M | 34.48M | 30.02M | 25.43M | 22.73M | 20.70M | 17.31M | 15.13M | 11.47M | 10.86M | 7.97M | 3.49M |
| EBITDA | 339.63M | 296.89M | 191.29M | 122.53M | 86.05M | 71.24M | 80.15M | 83.51M | 86.08M | 43.41M | 32.50M | 8.95M |
| EBITDA Ratio | 41.58% | 38.90% | 32.75% | 30.92% | 30.42% | 29.49% | 35.53% | 40.45% | 35.18% | 23.24% | 27.80% | 17.45% |
| Operating Income | 290.82M | 257.71M | 160.15M | 96.61M | 61.11M | 47.24M | 60.29M | 62.61M | 65.29M | 26.72M | 18.55M | 2.83M |
| Operating Income Ratio | 35.61% | 33.71% | 28.11% | 23.61% | 19.85% | 19.37% | 25.10% | 31.49% | 24.86% | 13.27% | 15.34% | 4.80% |
| Total Other Income/Expenses | -60.99K | -1.86M | -760.76K | -13.39M | -507.02K | 79.21K | -9.54M | 2.64M | 4.97M | -4.43M | -5.13M | -2.69M |
| Income Before Tax | 290.76M | 255.86M | 159.39M | 95.50M | 60.60M | 47.32M | 60.14M | 65.25M | 70.26M | 27.47M | 18.27M | 2.77M |
| Income Before Tax Ratio | 35.60% | 33.47% | 27.98% | 23.33% | 19.68% | 19.40% | 25.04% | 32.82% | 26.75% | 13.64% | 15.11% | 4.71% |
| Income Tax Expense | 36.86M | 20.48M | 13.46M | 8.66M | 4.22M | 3.46M | 7.13M | 7.93M | 9.40M | 5.97M | 2.72M | 479.86K |
| Net Income | 253.90M | 235.38M | 145.93M | 86.84M | 56.39M | 43.86M | 53.01M | 57.33M | 60.87M | 21.50M | 15.55M | 2.29M |
| Net Income Ratio | 31.09% | 30.79% | 25.62% | 21.22% | 18.31% | 17.99% | 22.07% | 28.83% | 23.17% | 10.67% | 12.86% | 3.89% |
| EPS | 0.43 | 0.42 | 0.26 | 0.17 | 0.11 | 0.08 | 0.11 | 0.15 | 0.17 | 0.14 | 0.11 | 0.03 |
| EPS Diluted | 0.43 | 0.42 | 0.26 | 0.17 | 0.11 | 0.08 | 0.11 | 0.15 | 0.17 | 0.14 | 0.11 | 0.03 |
| Weighted Avg Shares Out | 593.07M | 562.61M | 560.83M | 523.69M | 526.85M | 526.85M | 471.63M | 393.20M | 357.82M | 157.33M | 146.32M | 83.93M |
| Weighted Avg Shares Out (Dil) | 593.07M | 562.61M | 560.83M | 523.69M | 526.85M | 534.95M | 471.77M | 393.27M | 357.89M | 157.33M | 146.32M | 83.93M |
Source: https://incomestatements.info
Category: Stock Reports